Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Shiozaki Sounds Positive about Fact-Finding Study for Yearly NHI Price Cuts
October 23, 2014
- NIBIO, PMDA Join Hands in Advisory Services to Bring Academic Seeds to Market
October 22, 2014
- Editor’s Pick: Five Healthcare News Headlines for October 6 - October 17
October 21, 2014
- Takeda Takes Over Development of Glatiramer Acetate from Teva: Official
October 21, 2014
- Health Ministry Eyes Future Genomic Data Registration at National Medical Centers
October 21, 2014
- Applications Based on the Revised PAL to Be Accepted from Nov. 25
October 17, 2014
- MHLW to Report Lantus Biosimilars to PAFSC First Committee on Oct. 29
October 17, 2014
- NIBIO to Begin Drug Seed Optimization Project from FY2015
October 16, 2014
- PAFSC Second Committee to Discuss Janssen’s Combination Tablet for HIV Infection on Oct. 27
October 16, 2014
- 4 Die after Taking SGLT-2 Inhibitors, Causality under Scrutiny
October 15, 2014
- Japan Faces Rocky Road to Ratify Nagoya Protocol on Biodiversity
October 15, 2014
- MHLW Panel OKs Tweaked Requirements for New Development Request Scheme
October 15, 2014
- Council OKs Public-Knowledge Based Application for Solu-Cortef as a Treatment for Bronchial Asthma
October 15, 2014
- Govt Panel Says New Mixed-Care Scheme Is “Patient-Initiated” but Current System Isn’t
October 14, 2014
- National Healthcare Expenditure Hits Record 39 Trillion Yen in FY2012
October 14, 2014
- PFSB Issues Notification on Reporting of Malfunctions of Regenerative Medicine Products
October 14, 2014
- PFSB Issues Notification on Package Inserts of Regenerative Medicine Products
October 14, 2014
- PFSB Announces New Format for ADR Reporting to Be Used Starting in FY2016
October 14, 2014
- MOF Panel to Pitch Reference Pricing for Long-Listed Drugs, Price Cut in FY2015
October 9, 2014
- PMDA Begins Accepting Applications for Regulatory Review Schedule Meetings
October 9, 2014
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…